Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Gains from Investment Securities (2020 - 2025)

Rani Therapeutics Holdings (RANI) has 3 years of Gains from Investment Securities data on record, last reported at -$38000.0 in Q4 2024.

  • For Q4 2024, Gains from Investment Securities changed N/A year-over-year to -$38000.0; the TTM value through Sep 2025 reached -$38000.0, down 200.0%, while the annual FY2024 figure was $10.2 million, 54.0% up from the prior year.
  • Gains from Investment Securities reached -$38000.0 in Q4 2024 per RANI's latest filing, up from -$4.7 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $4.7 million in Q2 2024 and bottomed at -$4.7 million in Q3 2024.
  • Average Gains from Investment Securities over 3 years is $35750.0, with a median of $39500.0 recorded in 2021.
  • The widest YoY moves for Gains from Investment Securities: up 52466.67% in 2024, down 3428.57% in 2024.
  • A 3-year view of Gains from Investment Securities shows it stood at $70000.0 in 2021, then crashed by 290.0% to -$133000.0 in 2023, then skyrocketed by 71.43% to -$38000.0 in 2024.
  • Per Business Quant database, its latest 3 readings for Gains from Investment Securities were -$38000.0 in Q4 2024, -$4.7 million in Q3 2024, and $4.7 million in Q2 2024.